Liu WC, Janni W, Georgoulias V, et al. - Since, the tnAcity trial showed a notable PFS advantage with nab-paclitaxel (nab-P)/carboplatin (C) over nab-P/gemcitabine (G) or G/C in individuals with metastatic triple-negative breast cancer (mTNBC), examiners analyzed the association between circulating tumor cells (CTCs) dynamics and clinical advantage in all individuals (n = 126). The main analysis involved 126 individuals (Group 1, n = 24; Group 2, n = 54; and Group 3, n = 48). Efficiency results trended positively with chemotherapy-induced removal of CTCs, proposing that CTC clearance may prognosticate the chemosensitivity of mTNBC tumors.